Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders

Journal of Clinical Psychiatry

Volumn 76, Issue 11, 2015, Pages e1449-e1458

  Gerstenberg, Miriam ^a   Hauser, Marta ^b,c,d   Al Jadiri, Aseel ^b   Sheridan, Eva M ^b   Kishimoto, Taishiro ^b,e   Borenstein, Yehonatan ^f   Vernal, Ditte L ^g   David, Lisa ^b   Saito, Ema ^b,c   Landers, Sara E ^b   Carella, Morgan ^b   Singh, Sukhbir ^b   Carbon, Maren ^b   Jiménez Fernández, Sara ^h,i   Birnbaum, Michael L ^b,c   Auther, Andrea ^b,c   Carrión, Ricardo E ^b,c,d   Cornblatt, Barbara A ^b,c,d   Kane, John M ^b,c,d,j   Walitza, Susanne ^a   Correll, Christoph U ^b,c,d,j   more..

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY OF GRANADA   (Spain)

ⁱ Pathology Department   (Spain)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ADOLESCENT; ARTICLE; ATTENUATED PSYCHOSIS SYNDROME; COMORBIDITY; CONDUCT DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DSM-5; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEGATIVE SYNDROME; OPPOSITIONAL DEFIANT DISORDER; PERSONALITY DISORDER; POSITIVE SYNDROME; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SOCIAL ISOLATION; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; MENTAL DISORDERS; PERSONALITY DISORDERS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SYNDROME;

ADOLESCENT; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PERSONALITY DISORDERS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SYNDROME;

EID: 84958292319     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09435     Document Type: Article

References (72)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.
2. Fusar-Poli P, Yung AR. Should attenuated psychosis syndrome be included in DSM-5? Lancet. 2012;379(9816):591-592. doi:10.1016/S0140-6736(1)61507-9 PubMed
3. Yung AR, Woods SW, Ruhrmann S, et al. Whither the attenuated psychosis syndrome? Schizophr Bull. 2012;38(6):1130-1134. doi:10.1093/schbul/sbs108 PubMed
4. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220-229. doi:10.101/archgenpsychiatry.201.1472 PubMed
5. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill-advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010;120(1-3):23-37. doi:10.1016/j.schres.2010.03.015 PubMed
6. Niendam TA, Jalbrzikowski M, Bearden CE. Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. Neuropsychol Rev. 2009;19(3):280-293. doi:10.107/s1065-09-9108-z PubMed
7. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70(1):107-120. doi:10.101/jamapsychiatry.2013.269 PubMed
8. Carpenter WT, Regier D, Tandon R. Misunderstandings about attenuated psychosis syndrome in the DSM-5. Schizophr Res. 2014;152(1):303. doi:10.1016/j.schres.2013.1.020 PubMed
9. Schimmelmann BG, Walger P, Schultze-Lutter F. The significance of at-risk symptoms for psychosis in children and adolescents. Can J Psychiatry. 2013;58(1):32-40. PubMed
10. Ziermans TB, Schothorst PF, Sprong M, et al. Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr Res. 2011;126(1-3):58-64. doi:10.1016/j.schres.2010.10.02 PubMed
11. Welsh P, Tiffin PA. The 'at-risk mental state' for psychosis in adolescents: clinical presentation, transition and remission. Child Psychiatry Hum Dev. 2014;45(1):90-98. doi:10.107/s10578-013-0380-z PubMed
12. Lindgren M, Manninen M, Kalska H, et al. Predicting psychosis in a general adolescent psychiatric sample. Schizophr Res. 2014;158(1-3):1-6. doi:10.1016/j.schres.2014.06.028 PubMed
13. Meyer SE, Bearden CE, Lux SR, et al. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol. 2005;15(3):434-451. doi:10.1089/cap.205.15.434 PubMed
14. Kelleher I, Murtagh A, Molloy C, et al. Identification and characterization of prodromal risk syndromes in young adolescents in the community: a populationbased clinical interview study. Schizophr Bull. 2012;38(2):239-246. doi:10.1093/schbul/sbr164 PubMed
15. Carpenter WT. Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull. 2009;35(5):841-843. doi:10.1093/schbul/sbp071 PubMed
16. Tsuang MT, Van Os J, Tandon R, et al. Attenuated psychosis syndrome in DSM-5. Schizophr Res. 2013;150(1):31-35. doi:10.1016/j.schres.2013.05.04 PubMed
17. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35(5):894-908. doi:10.1093/schbul/sbp027 PubMed
18. Woods SW, Walsh BC, Saksa JR, et al. The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res. 2010;123(2-3):199-207. doi:10.1016/j.schres.2010.08.012 PubMed
19. Correll CU, Hauser M, Auther AM, et al. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry. 2010;51(4):390-431. doi:10.1/j.1469-7610.2010.0235.x PubMed
20. Wilkinson G. Wide Range Achievement Test 3-Administration Manual. Wilmington, DE: Jastak Associates; 1993.
21. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
22. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-988. doi:10.1097/04583-197070-021 PubMed
23. Pfohl B, Blum N, Zimmermann M. Structured Interview for DSM-IV Personality: SIDP-IV. Washington, DC: American Psychiatric Pub.; 1997.
24. Cicchetti D, Crick NR. Precursors and diverse pathways to personality disorder in children and adolescents. Dev Psychopathol. 2009;21(3):683-685. doi:10.1017/S0954579409038 PubMed
25. Bornovalova MA, Hicks BM, Iacono WG, et al. Stability, change, and heritability of borderline personality disorder traits from adolescence to adulthood: a longitudinal twin study. Dev Psychopathol. 2009;21(4):1335-1353. doi:10.1017/S09545794090186 PubMed
26. McGlashan T, Walsh B, Woods S. The Psychosis-Risk Syndrome. Handbook for Diagnosis and Follow-Up. New York, NY: Oxford University Press; 2010.
27. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799-812. doi:10.246/pr0.1962.10.3.79
28. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449. doi:10.176/api.ajp.162.3.41 PubMed
29. Lyne JP, Kinsella A, O'Donoghue B. Can we combine symptom scales for collaborative research projects? J Psychiatr Res. 2012;46(2):233-238. doi:10.1016/j.jpsychires.201.10.02 PubMed
30. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389http://bjp. rcpsych.org/content/134/4/382.short. Accessed July 18, 2013. doi:10.192/bjp.134.4.382 PubMed
31. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435. doi:10.192/bjp.13.5.429htp:/w.ncbi.nlm.nih.gov/pubmed/728692 PubMed
32. Guy W. Clinical Global Impression scale. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare; 1976;218-222. http://www.incamresearch.ca/content/clinical-globalimpression-scale. Accessed August 16, 2013.
33. Amador X, Strauss D. The Scale to Assess Unawareness of Mental Disorder (SUMD). New York, NY: Columbia University and New York State Psychiatric Institute; 1990.
34. Hall RC. Global Assessment of Functioning: a modified scale. Psychosomatics. 1995;36(3):267-275. doi:10.1016/S03-3182(95)716-8 PubMed
35. Niendam T, Bearden C, Johnson J, et al. Global Functioning: Role Scale (GF: Role). Los Angeles, CA: University of California; 2006.
36. Auther A, Smith C, Cornblatt B. Global Functioning: Social Scale (GF: Social). Glen Oaks, NY: Zucker-Hillside Hospital; 2006.
37. Rosenthal R, Rosnow RL. Essentials of behavioral research: Methods and data analysis. 2nd ed. New York, NY: McGraw-Hill; 1991.
38. Kline E, Wilson C, Ereshefsky S, et al. Psychosis risk screening in youth: a validation study of three self-report measures of attenuated psychosis symptoms. Schizophr Res. 2012;141(1):72-77. doi:10.1016/j.schres.2012.07.02 PubMed
39. Lindgren M, Manninen M, Laajasalo T, et al. The relationship between psychotic-like symptoms and neurocognitive performance in a general adolescent psychiatric sample. Schizophr Res. 2010;123(1):77-85. doi:10.1016/j.schres.2010.07.025 PubMed
40. Schultze-Lutter F, Michel C, Ruhrmann S, et al. Prevalence and clinical significance of DSM-5-attenuated psychosis syndrome in adolescents and young adults in the general population: the Bern Epidemiological At-Risk (BEAR) Study. Schizophr Bull. 2014;40(6):1499-1508. 10.1093/schbul/sbt171 PubMed
41. Kelleher I, Connor D, Clarke MC, et al. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of populationbased studies. Psychol Med. 2012;42(9):1857-1863. doi:10.1017/S032917102960 PubMed
42. van Os J, Linscott RJ, Myin-Germeys I, et al. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med. 2009;39(2):179-195. doi:10.1017/S0329170803814 PubMed
43. Thapar A, Heron J, Jones RB, et al. Trajectories of change in self-reported psychotic-like experiences in childhood and adolescence. Schizophr Res. 2012;140(1-3):104-109. doi:10.1016/j.schres.2012.06.024 PubMed
44. Schultze-Lutter F, Klosterkötter J, Ruhrmann S. Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophr Res. 2014;154(1-3):100-106. doi:10.1016/j.schres.2014.02.010 PubMed
45. Ruhrmann S, Schultze-Lutter F, Salokangas RKR, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67(3):241-251. doi:10.101/archgenpsychiatry.209.206 PubMed
46. Meng H, Schimmelmann BG, Koch E, et al. Basic symptoms in the general population and in psychotic and non-psychotic psychiatric adolescents. Schizophr Res. 2009;111(1-3):32-38. doi:10.1016/j.schres.209.03.01 PubMed
47. Fux L, Walger P, Schimmelmann BG, et al. The Schizophrenia Proneness Instrument, Child and Youth version (SPI-CY): practicability and discriminative validity. Schizophr Res. 2013;146(1-3):69-78. doi:10.1016/j.schres.2013.02.014 PubMed
48. Simon AE, Velthorst E, Nieman DH, et al. Ultra high-risk state for psychosis and nontransition: a systematic review. Schizophr Res. 2011;132(1):8-17. doi:10.1016/j.schres.201.07.02 PubMed
49. Svirskis T, Korkeila J, Heinimaa M, et al. Axis-I disorders and vulnerability to psychosis. Schizophr Res. 2005;75(2-3):439-446. doi:10.1016/j.schres.204.1.02 PubMed
50. Salokangas RKR, Ruhrmann S, von Reventlow HG, et al; EPOS group. Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophr Res. 2012;138(2-3):192-197. doi:10.1016/j.schres.2012.03.08 PubMed
51. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. doi:10.101/archpsyc.62.6.593 PubMed
52. Gaudiano BA, Zimmerman M. Prevalence of attenuated psychotic symptoms and their relationship with DSM-IV diagnoses in a general psychiatric outpatient clinic. J Clin Psychiatry. 2013;74(2):149-155. doi:10.408/JCP.12m078 PubMed
53. Manninen M, Lindgren M, Therman S, et al. Clinical high-risk state does not predict later psychosis in a delinquent adolescent population. Early Interv Psychiatry. 2014;8(1):87-90. doi:10.1/eip.12045 PubMed
54. Schultze-Lutter F, Klosterkötter J, Michel C, et al. Personality disorders and accentuations in at-risk persons with and without conversion to first-episode psychosis. Early Interv Psychiatry. 2012;6(4):389-398. 10.1111/j.1751-7893.2011.00324.x PubMed
55. Barnow S, Arens EA, Sieswerda S, et al. Borderline personality disorder and psychosis: a review. Curr Psychiatry Rep. 2010;12(3):186-195. doi:10.107/s1920-010-0107-9 PubMed
56. Häfner H, an der Heiden W. The course of schizophrenia in the light of modern followup studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 4):14-26. doi:10.107/PL014180 PubMed
57. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-370. doi:10.1093/schbul/2.2.353 PubMed
58. Davidson M, Reichenberg A, Rabinowitz J, et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999;156(9):1328-1335. PubMed
59. Dworkin RH, Cornblatt BA, Friedmann R, et al. Childhood precursors of affective vs social deficits in adolescents at risk for schizophrenia. Schizophr Bull. 1993;19(3):563-577. doi:10.1093/schbul/19.3.563 PubMed
60. Lencz T, Smith CW, Auther A, et al. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004;68(1):37-48. doi:10.1016/S0920-964(03)0214-7 PubMed
61. Simon AE, Cattapan-Ludewig K, Gruber K, et al. Subclinical hallucinations in adolescent outpatients: an outcome study. Schizophr Res. 2009;108(1-3):265-271. doi:10.1016/j.schres.208.12.018 PubMed
62. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60(1):21-32. doi:10.1016/S0920-964(02)0167-6 PubMed
63. Yung AR, Phillips LJ, Yuen HP, et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67(2-3):131-142. doi:10.1016/S0920-964(03)0192-0 PubMed
64. Cornblatt BA, Carrión RE, Addington J, et al. Risk factors for psychosis: impaired social and role functioning. Schizophr Bull. 2012;38(6):1247-1257. doi:10.1093/schbul/sbr136 PubMed
65. Valmaggia LR, Stahl D, Yung AR, et al. Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. Psychol Med. 2013;43(11):2311-2325. doi:10.1017/S032917130251 PubMed
66. Kelleher I, Corcoran P, Keeley H, et al. Psychotic symptoms and population risk for suicide attempt: a prospective cohort study. JAMA Psychiatry. 2013;70(9):940-948. doi:10.101/jamapsychiatry.2013.140 PubMed
67. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629-635. doi:10.1016/j.euroneuro.209.04.08 PubMed
68. Olfson M, Blanco C, Liu S-M, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247-1256. doi:10.101/archgenpsychiatry.2012.647 PubMed
69. Birnbaum ML, Saito E, Gerhard T, et al. Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. Curr Psychiatry Rep. 2013;15(8):382. doi:10.107/s1920-013-0382-3 PubMed
70. Wigman JTW, van Nierop M, Vollebergh WAM, et al. Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity-implications for diagnosis and ultra-high risk research. Schizophr Bull. 2012;38(2):247-257. doi:10.1093/schbul/sbr196 PubMed
71. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70(9):1206-1212. doi:10.408/JCP.08r0472 PubMed
72. McGorry PD, Purcell R, Goldstone S, et al. Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Curr Opin Psychiatry. 2011;24(4):301-306. doi:10.1097/YCO.0b013e328347a09 PubMed